• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Emerging Technology Market
    Emerging Technology News
    Emerging Technology Stocks
    • Emerging Technology Market
    • Emerging Technology News
    • Emerging Technology Stocks
    3d printing investing

    Organovo Holdings Announces Second Quarter 2016 Fiscal Results and Long-Range Outlooks

    Morag Mcgreevey
    Nov. 10, 2015 07:50AM PST
    Emerging Technology

    Organovo Holdings (NYSE MKT:ONVO) has announced its financial results for the fiscal second quarter of 2016, as well as its full-year fiscal and long-range outlooks.

    Organovo Holdings (NYSE MKT:ONVO) has announced its financial results for the fiscal second quarter of 2016, as well as its full-year fiscal and long-range outlooks.
    According to the press release:

    Net loss was $11.3 million, or $0.12 per share, for the fiscal second quarter of 2016, as compared to $8.9 million, or $0.11 per share, for the fiscal second quarter of 2015.
    Organovo reported fiscal second-quarter total revenue of $0.3 million, which consisted of $0.2 million of products and services revenue and $0.1 million of collaborations and grants revenue.  Total revenue increased 502 percent versus the comparable period of fiscal 2015.  Products and services revenue, which primarily represents revenue from the exVive3DTM Human Liver Tissue research service and product, increased by $0.2 million from the year-ago period.  The Company commercially released the exVive3D Human Liver Tissue in November 2014.
    The Company also achieved its next milestone for its kidney program ahead of schedule.  Functional validation of its kidney tissue, due to be achieved in December 2015, was completed in October 2015. The Company is preparing the data, which includes functional measurement of tissue performance, as well as characteristic toxic behavior of known molecules, for submission to a peer-reviewed journal.  Organovo remains on schedule to initiate contracting for this product in the calendar third quarter of 2016.
    “We affirmed our fiscal 2016 and long-range outlook across the board today and are pleased with our momentum through the fiscal second quarter,” said Keith Murphy, CEO, Organovo.  “We participate in attractive and growing markets with critical unmet needs, benefit from favorable competitive dynamics that come with a first mover advantage, and own a leading technology with a strong IP portfolio.  Taking all this together, we expect solid revenue growth through an expanding product and service platform.”

    Click here to read the full press release.


     
    organovo holdings3d printing investingfinancial results
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    A floating DNA double helix above a hand with a blue background.

    Top 5 NASDAQ Genetics Stocks (Updated January 2025)

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Emerging Technology Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×